Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)
WARNINGS AND PRECAUTIONS
- In clinical trials of 2688 adult RA patients treated with intravenous Orencia, there were two cases (<0.1%) of anaphylaxis or anaphylactoid reactions…
Warnings and Precautions
- to include information regarding serious infections.